Health status following an acute exacerbation of chronic bronchitis (AECB) is better in patients receiving gemifloxacin compared with clarithromycin Source: Eur Respir J 2001; 18: Suppl. 33, 542s Year: 2001
Efficacy of azithromycin vs. ciprofloxacin in the treatment of patients with acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 544s Year: 2002
Short and long-term outcomes of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB): The MOSAIC study Source: Eur Respir J 2003; 22: Suppl. 45, 566s Year: 2003
Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in PROTEKT years 1–5 (1999–2004) Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients Year: 2006
Short-term efficacy of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB): A multivariate analysis from the MOSAIC study Source: Eur Respir J 2003; 22: Suppl. 45, 351s Year: 2003
Risk factors associated with observed severity and frequency of 137 first exacerbations (AECB) in 618 consecutive chronic bronchitis (CB) outpatients Source: Eur Respir J 2002; 20: Suppl. 38, 543s Year: 2002
Telithromycin is effective in the treatment of patients with acute exacerbations of chronic bronchitis and risk factors for morbidity Source: Eur Respir J 2002; 20: Suppl. 38, 545s Year: 2002
Molecular epidemiology of acute exacerbations of chronic bronchitis (AECB) Source: Annual Congress 2009 - Exacerbations of COPD: new findings Year: 2009
Clinical evaluation of patients with acute exacerbation of chronic bronchitis treated emperically with telithromycin Source: Eur Respir J 2004; 24: Suppl. 48, 638s Year: 2004
Correlation between eradication of infecting organism on days 3-5 of antibiotic therapy and clinical cure in patients with acute exacerbations of chronic bronchitis (AECB) Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007
Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results Source: Eur Respir J 2012; 40: 17-27 Year: 2012
Prevalence and risk factors for Aspergillus spp. colonization in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD): The multi-center FUNGI-COPD study Source: Annual Congress 2010 - Various aspects of respiratory epidemiology Year: 2010
Antibacterial activity of telithromycin (TEL) and comparators against bacterial pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in the PROTEKT study 1999–2002 Source: Eur Respir J 2004; 24: Suppl. 48, 641s Year: 2004
Does the condition of chronic obstructive pumonary disease (COPD) have a prognostic benefit in patients with community-acquired pneumonia (CAP)? Source: Eur Respir J 2003; 22: Suppl. 45, 338s Year: 2003
Greatest International ANti-infective Trial (GIANT) – the German cohort: moxifloxacin treatment provides short- and long-term benefits in AECB patients Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients Year: 2006
Long-term benefits of antibiotic treatment in reducing recurrence rates and resource utilization in acute exacerbations of chronic bronchitis (AECB) Source: Annual Congress 2003 - Outcome of acute exacerbations in COPD Year: 2003
Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis Source: Eur Respir J 2001; 17: 928-933 Year: 2001
Placebo-controlled, double-blind trial of chronic, intermittent ‘pulse‘ therapy of moxifloxacin to prevent acute exacerbations in COPD patients with chronic bronchitis: baseline data Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients Year: 2006
Outcome of patients following hospitalization with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) , with and without cardiovascular risk factors Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016